



RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

PATENT  
PC8626BJTJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE DIVISIONAL APPLICATION OF:

**William J. Curatolo, et al.**

SERIAL NO.: 09/577,059

FILED: May 22, 2000

FOR: **Controlled-Release Dosage  
Forms of Azithromycin**

Assistant Commissioner for Patents  
Washington, D.C. 20231

EXAMINER: R. Dewitty  
I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as First Class Mail in an  
envelope addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231 on

this 3rd day of December 20 01

By 

Request For Reconsideration Under 37 CFR 1.111

Sir:

This is in response to the Office Action of June 4, 2001 in the above-identified application, the term for response having been extended three (3) months by enclosing the appropriate fee and petition herewith.

In response to the Office Action, please consider the following comments and traversal of the rejection.

REMARKS

As a preliminary matter, Applicants hereby affirm, without traverse, the provisional election made on 4/1/01 in a telephone conversation with Examiner DeWitty - - hydroxypropyl methylcellulose, a tablet, a cylinder, and a coated tablet, and concur with the claims currently withdrawn from consideration as not being generic - - claims 77-79, 87-92, 130-132, and 140-145. Applicants also agree that remaining claims 72-76, 80-86, 93-129, 133-139, and 146-148 are generic to the elected species. From the context and apparent intent of the Office Action, and despite the use of the phrase "non-elected invention" (last line of paragraph 1 on page 3) which is generally associated with a restriction requirement, Applicants are assuming that the election requirement made by the Examiner is solely an election of species, and that no requirement to separately elect between separate inventions (as opposed to between separate species) was made.